BT-20細(xì)胞，人乳癌細(xì)胞

簡要描述：BT-20細(xì)胞，人乳癌細(xì)胞
ATCC 細(xì)胞|細(xì)胞系|細(xì)胞株|腫瘤細(xì)胞|細(xì)胞；細(xì)胞庫管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和*培養(yǎng)條件！

產(chǎn)品型號：HTB-19
廠商性質(zhì)：生產(chǎn)廠家
更新時間：2024-11-16
訪問量：1595

產(chǎn)品咨詢聯(lián)系我們

產(chǎn)品分類

Product Category

細(xì)胞庫

細(xì)胞原代牛、狗、雞、鴨、魚原代細(xì)胞羊原代細(xì)胞豬原代細(xì)胞兔原代細(xì)胞小鼠原代細(xì)胞大鼠原代細(xì)胞人原代細(xì)胞培養(yǎng)基原代細(xì)胞凍存液 ATCC 人乳腺癌豬正常細(xì)胞豬睪丸細(xì)胞系人膠質(zhì)瘤細(xì)胞人成骨細(xì)胞人永生化肝細(xì)胞人肝癌細(xì)胞人卵巢癌細(xì)胞人結(jié)直腸腺癌人經(jīng)典小細(xì)胞肺癌細(xì)胞人小細(xì)胞肺癌細(xì)胞人結(jié)直腸腺癌細(xì)胞人鼻腔上皮細(xì)胞中國倉鼠卵巢懸浮細(xì)胞嗜性逆轉(zhuǎn)錄病毒包裝穩(wěn)定細(xì)胞株小鼠神經(jīng)細(xì)胞瘤人眼脈洛膜黑色素瘤 PT67 逆轉(zhuǎn)錄酶病毒包裝細(xì)胞鴨子胚胎成纖維細(xì)胞豬腎細(xì)胞系昆蟲細(xì)胞貓腎細(xì)胞恒河猴胚腎細(xì)胞倉鼠卵巢細(xì)胞負(fù)鼠腎細(xì)胞倉鼠肺細(xì)胞果蠅胚胎細(xì)胞家貓肺成纖維樣細(xì)胞雞胚細(xì)胞豚鼠心肌來源細(xì)胞豚鼠肺成纖維樣細(xì)胞豚鼠皮膚成纖維樣細(xì)胞狗腎細(xì)胞非洲綠猴胚胎腎上皮細(xì)胞猴胚胎腎上皮細(xì)胞長臂猿淋巴瘤新生牛眼囊成纖維細(xì)胞黑化大家鼠肺成纖維樣細(xì)胞俄勒岡地鼠細(xì)胞家兔皮膚成纖維樣細(xì)胞昆蟲卵巢細(xì)胞人胸膜瘤細(xì)胞非洲綠猴腎細(xì)胞 VERO 衍生株（SVP）白化金黃地鼠肺成纖維樣細(xì)胞黃胸鼠肺成纖維樣細(xì)胞白鰱尾鰭細(xì)胞蝙蝠肺細(xì)胞草魚腎細(xì)胞系大黃魚腎細(xì)胞猴腎細(xì)胞系犬腎細(xì)胞系人結(jié)腸直腸腺癌豬肺泡巨噬細(xì)胞 PFHSA05（TLL2）人重組特洛德樣蛋白因子 PFHSA04 （BMP1）人重組骨誘導(dǎo)因子人乳腺癌細(xì)胞結(jié)腸癌細(xì)胞成纖維細(xì)胞人胚腎細(xì)胞動物卵巢細(xì)胞動物胚胎細(xì)胞動物肺細(xì)胞肋骨來源細(xì)胞成纖維樣細(xì)胞動物上皮細(xì)胞動物肝臟細(xì)胞可誘導(dǎo)表達(dá)穩(wěn)定細(xì)胞株動物氣管細(xì)胞動物腎細(xì)胞動物巨噬細(xì)胞人正常細(xì)胞人腫瘤細(xì)胞、癌細(xì)胞小鼠正常細(xì)胞小鼠腫瘤細(xì)胞、癌細(xì)胞大鼠正常細(xì)胞大鼠腫瘤細(xì)胞其它動物細(xì)胞查看全部產(chǎn)品

相關(guān)文章

詳細(xì)介紹

BT-20細(xì)胞，人乳癌細(xì)胞

ATCC^® Number:

HTB-19™

Price:

Designations:BT-20Depositors:EY LasfarguesBiosafety Level:1Shipped:frozenMedium & Serum:See PropagationGrowth Properties:adherentOrganism:Homo sapiensMorphology:epithelial Source:Organ: mammary gland; breast Disease: carcinomaPermits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.Isolation:Isolation date: 1958Applications:BT-20 cells are negative for estrogen receptor, but do express an estrogen receptor mRNA that has deletion of exon 5. This breast tumor line was established by E.Y. Lasfargues and L. Ozzello in 1958 by isolation and c*tion of cells spilling out of the tumor when it was cut in thin slices.Tumorigenic:YesBT-20細(xì)胞，人乳癌細(xì)胞Reverse Transcript:negativeAntigen Expression:HLA A1, Bw16 (+/-)DNA Profile (STR):Amelogenin: X CSF1PO: 12 D13S317: 11 D16S539: 11,14 D5S818: 12 D7S820: 10 THO1: 7,9.3 TPOX: 11 vWA: 16,17Cytogenetic Analysis:Normal chromosomes N3, N4, N9, N13, N14, and X may be absent. The markers der(11)t(11;?)(q25;?) (M1); der(1)t(1;3)(p22?;p13?) (M2); and der(2)t(2;?) (q37;?) (M5) were detected by W.A. Nelson-Rees, et al., Int. J. Cancer 16: 74-85, 1975.Isoenzymes:AK-1, 1-2 ES-D, 1 G6PD, B GLO-I, 1-2 PGM1, 1 PGM3, 1Age:74 yearsGender:femaleEthnicity:CaucasianComments:The cells express the WNT3 and the WNT7B oncogenes [PubMed: 8168088]. This breast tumor line was established by E.Y. Lasfargues and L. Ozzello in 1958 by isolation and c*tion of cells spilling out of the tumor when it was cut in thin slices. A mycoplasma contaminant was discovered and eliminated early in 1972. Growth of BT-20 cells is inhibited by tumor necrosis factor alpha (TNF alpha). BT-20 cells are negative for estrogen receptor, but do express an estrogen receptor mRNA that has deletion of exon 5.Propagation:ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°CSubculturing:Protocol:Remove and discard culture medium.Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.Add appropriate aliquots of the cell suspension to new culture vessels.Incubate cultures at 37°C.Subc*tion Ratio: A subc*tion ratio of 1:2 to 1:4 is recommended Medium Renewal: 2 to 3 times per weekPreservation:Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phaseRelated Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003recommended serum:ATCC 30-2020References:21405: Sugarman BJ, et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230: 943-945, 1985. PubMed: 393311122536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 83387123079: Lan MS, et al. Polypeptide core of a human pancreatic tumor mucin antigen. Cancer Res. 50: 2997-3001, 1990. PubMed: 233490323110: Castles CG, et al. Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res. 53: 5934-5939, 1993. PubMed: 826140623113: Huguet EL, et al. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res. 54: 2615-2621, 1994. PubMed:816808823212: Lasfargues EY, Ozzello L. C*tion of human breast carcinomas. J. Natl. Cancer Inst. 21: 1131-1147, 1958. PubMed: 1361153723226: Pollack MS, et al. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66: 1003-1012, 1981. PubMed: 701721232275: Littlewood-Evans AJ, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 57: 5386-5390, 1997. PubMed: 939376432488: Geiger T, et al. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des. 13: 35-45, 1998. PubMed: 9474241

產(chǎn)品咨詢

留言框

產(chǎn)品：
您的單位：
您的姓名：
聯(lián)系電話：
常用郵箱：
省份：
詳細(xì)地址：
補(bǔ)充說明：
驗(yàn)證碼：

請輸入計(jì)算結(jié)果（填寫阿拉伯?dāng)?shù)字），如：三加四=7

上一篇：JEG 細(xì)胞，人絨毛膜癌細(xì)胞
下一篇：CRL-9589AML-193細(xì)胞，人急性單核細(xì)胞白血病

亚洲日本精品国产第一区二区_香港经典a毛片免费观看hd_欧美放荡的少妇_亚洲va久久久噜噜噜久久_少妇装睡让我滑了进去

BT-20細(xì)胞， 人乳癌細(xì)胞

留言框

產(chǎn)品：

您的單位：

您的姓名：

聯(lián)系電話：

常用郵箱：

省份：

詳細(xì)地址：

補(bǔ)充說明：

驗(yàn)證碼：

BT-20細(xì)胞，人乳癌細(xì)胞